Douglas J G, Forrest J A, Prowse C V, Cash J D, Finlayson N D
Gut. 1979 Jul;20(7):565-7. doi: 10.1136/gut.20.7.565.
In eight patients with cirrhosis of the liver and portal hypertension an intravenous infusion of lysine vasopressin induced a rapid increase in the plasma level of the fibrinolytic proenzyme plasminogen activator. In contrast, triglycyl lysine vasopressin (glypressin; GVP), in a dose known to lower portal venous pressure, produced no fibrinolytic response. This lack of fibrinolytic response represents an advantage of GVP over lysine vasopressin in addition to its longer in vivo half-life and lower cardiotoxicity. Clinical trials of GVP in the treatment of bleeding oesophageal varices are needed.
在8例肝硬化和门静脉高压患者中,静脉输注赖氨酸加压素可使纤溶酶原激活物(一种纤溶酶原酶)的血浆水平迅速升高。相比之下,已知能降低门静脉压力的剂量的三甘氨酰赖氨酸加压素(甘氨加压素;GVP)却未产生纤溶反应。除了其较长的体内半衰期和较低的心脏毒性外,这种缺乏纤溶反应代表了GVP相对于赖氨酸加压素的一个优势。需要对GVP治疗食管静脉曲张出血进行临床试验。